Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors
Compose a Response to This Article
Other responses
No responses have been published for this article.